BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33989290)

  • 1. Iron activates microglia and directly stimulates indoleamine-2,3-dioxygenase activity in the N171-82Q mouse model of Huntington's disease.
    Donley DW; Realing M; Gigley JP; Fox JH
    PLoS One; 2021; 16(5):e0250606. PubMed ID: 33989290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Huntingtons Disease Mice Infected with Toxoplasma gondii Demonstrate Early Kynurenine Pathway Activation, Altered CD8+ T-Cell Responses, and Premature Mortality.
    Donley DW; Olson AR; Raisbeck MF; Fox JH; Gigley JP
    PLoS One; 2016; 11(9):e0162404. PubMed ID: 27611938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
    Mazarei G; Budac DP; Lu G; Lee H; Möller T; Leavitt BR
    Exp Neurol; 2013 Nov; 249():144-8. PubMed ID: 23994717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology.
    Savage JC; St-Pierre MK; Carrier M; El Hajj H; Novak SW; Sanchez MG; Cicchetti F; Tremblay MÈ
    J Neuroinflammation; 2020 Apr; 17(1):98. PubMed ID: 32241286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear translocation of STAT5 initiates iron overload in huntington's disease by up-regulating IRP1 expression.
    Niu L; Zhou Y; Wang J; Zeng W
    Metab Brain Dis; 2024 Apr; 39(4):559-567. PubMed ID: 38261161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin.
    Connolly C; Magnusson-Lind A; Lu G; Wagner PK; Southwell AL; Hayden MR; Björkqvist M; Leavitt BR
    Neuroscience; 2016 Jun; 325():74-88. PubMed ID: 27033979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
    Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
    Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease.
    Berggren KL; Chen J; Fox J; Miller J; Dodds L; Dugas B; Vargas L; Lothian A; McAllum E; Volitakis I; Roberts B; Bush AI; Fox JH
    Redox Biol; 2015; 4():363-74. PubMed ID: 25703232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant huntingtin expression in microglia is neither required nor sufficient to cause the Huntington's disease-like phenotype in BACHD mice.
    Petkau TL; Hill A; Connolly C; Lu G; Wagner P; Kosior N; Blanco J; Leavitt BR
    Hum Mol Genet; 2019 May; 28(10):1661-1670. PubMed ID: 30624705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.
    Sathyasaikumar KV; Stachowski EK; Amori L; Guidetti P; Muchowski PJ; Schwarcz R
    J Neurochem; 2010 Jun; 113(6):1416-25. PubMed ID: 20236387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.
    Mazarei G; Budac DP; Lu G; Adomat H; Tomlinson Guns ES; Möller T; Leavitt BR
    J Neurochem; 2013 Dec; 127(6):852-67. PubMed ID: 23786539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IKKβ slows Huntington's disease progression in R6/1 mice.
    Ochaba J; Fote G; Kachemov M; Thein S; Yeung SY; Lau AL; Hernandez S; Lim RG; Casale M; Neel MJ; Monuki ES; Reidling J; Housman DE; Thompson LM; Steffan JS
    Proc Natl Acad Sci U S A; 2019 May; 116(22):10952-10961. PubMed ID: 31088970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington's disease.
    Boros FA; Klivényi P; Toldi J; Vécsei L
    Expert Opin Ther Targets; 2019 Jan; 23(1):39-51. PubMed ID: 30449219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
    Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
    Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TYROBP/DAP12 knockout in Huntington's disease Q175 mice cell-autonomously decreases microglial expression of disease-associated genes and non-cell-autonomously mitigates astrogliosis and motor deterioration.
    Creus-Muncunill J; Haure-Mirande JV; Mattei D; Bons J; Ramirez AV; Hamilton BW; Corwin C; Chowdhury S; Schilling B; Ellerby LM; Ehrlich ME
    J Neuroinflammation; 2024 Mar; 21(1):66. PubMed ID: 38459557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease.
    Mazarei G; Leavitt BR
    J Huntingtons Dis; 2015; 4(2):109-18. PubMed ID: 26397892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice.
    Corona AW; Norden DM; Skendelas JP; Huang Y; O'Connor JC; Lawson M; Dantzer R; Kelley KW; Godbout JP
    Brain Behav Immun; 2013 Jul; 31():134-42. PubMed ID: 22926082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment.
    Giorgini F; Möller T; Kwan W; Zwilling D; Wacker JL; Hong S; Tsai LC; Cheah CS; Schwarcz R; Guidetti P; Muchowski PJ
    J Biol Chem; 2008 Mar; 283(12):7390-400. PubMed ID: 18079112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of copper ion mediated Huntington's disease progression.
    Fox JH; Kama JA; Lieberman G; Chopra R; Dorsey K; Chopra V; Volitakis I; Cherny RA; Bush AI; Hersch S
    PLoS One; 2007 Mar; 2(3):e334. PubMed ID: 17396163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.